Eisai, Merck and Lenvima

Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve overall survival in patients with a type of esophageal cancer in a late-stage trial,
Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. | Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way.
Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer
Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen in GIT cancer. Read more here.
Merck’s Keytruda Combo Fails to Extend Survival in Phase III GI Cancer
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against its limits after racking up around 50 approvals since getting its first FDA nod in September 2014.
Merck and Eisai report mixed results in Phase 3 cancer trial
Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, which evaluated the efficacy of the combination therapy KEYTRUDA and LENVIMA for patients with advanced gastroesophageal adenocarcinoma.
Merck, Eisai provide update on Phase 3 LEAP-015 trial
Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA,
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday said the Phase 3 study of Keytruda plus Lenvima in combination with chemotherapy showed a statistically significant improvement in progression-free survival,
FiercePharma8h
After slow rollout, Merck's Winrevair poised for 'strong uptake' in 2025: Leerink
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
Kennedy would keep legal fees from Merck cases if confirmed
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...
7 Best Pharmaceutical Stocks to Buy for Income
The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...
health.wusf.usf.edu1d
RFK Jr. plans to keep a financial stake in lawsuits against the drugmaker Merck
RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, ...
Merck KGaA says high asset prices call for prudent M&A approach
The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a ...
MM&M2d
The Escalator: Merck, Novartis, Arvinas and more
Avadel Pharmaceuticals appointed Sev Melkonian as VP of patient services, distribution and reimbursement. Experity appointed ...
Purdue University7d
Purdue aims to speed evolution of pharma manufacturing in collaboration with Lilly and Merck
Purdue partners with Eli Lilly and Merck to launch the Young Institute Pharmaceutical Manufacturing Consortium, focusing on sterile injectables.